In breast tumors, the acetylation of DDX17 enhances p53-dependent MDM2 promoter activation, stimulates MDM2 transcription, reduces the p53 level by promoting the p53-MDM2 negative feedback loop, and promotes carcinogenesis (117) (Figure 3). This evidence concerns the gene MDM2 and breast neoplasm.